NVO Stock Summary and Trading Ideas (Novo Nordisk A/S | NYSE:NVO)

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.

As of February 25, 2026, NVO stock price declined to $38.16 with 42,099,790 million shares trading.

NVO has a beta of 1.35, meaning it tends to be more sensitive to market movements. NVO has a correlation of 0.12 to the broad based SPY ETF.

NVO has a market cap of $169.55 billion. This is considered a Large Cap stock.

Last quarter Novo Nordisk A/S reported $12 billion in Revenue and $1.00 earnings per share. This beat revenue expectation by $255 million and exceeded earnings estimates by $.11.

In the last 3 years, NVO traded as high as $148.15 and as low as $37.65.

The top ETF exchange traded funds that NVO belongs to (by Net Assets): PVAL, PPH, AVDE, FTHI, WCMI.

NVO has underperformed the market in the last year with a price return of -56.0% while the SPY ETF gained +17.3%. NVO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.1% and -22.3%, respectively, while the SPY returned +3.9% and +0.1%, respectively.

NVO support price is $37.39 and resistance is $39.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.